Literature DB >> 7288282

In vitro transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal flora, with particular reference to the mutual conversion between the two bile acids.

S Hirano, N Masuda, H Oda.   

Abstract

Nine fecal samples from four healthy subjects were examined for their ability to transform chenodeoxy-cholic acid (CDCA) and ursodeoxycholic acid (UDCA) in in vitro anaerobic broth cultures. Seven samples converted CDCA and UDCA into each other (more than 50% of CDCA was converted into UDCA while 10% or less of UDCA was converted into CDCA), and produced 7-keto-lithocholic acid and lithocholic acid equally from both acids. No alteration of the 7 beta-hydroxy group of UDCA was demonstrated by two fecal samples that failed to perform mutual 7-epimerization, suggesting the conversion of UDCA into lithocholic acid via CDCA. The 3 alpha-hydroxy groups of these substrate and metabolite bile acids were invariably partially epimerized to 3 beta-hydroxy groups by all the fecal samples. Evidence is presented for the prevalence of these 7- and 3-epimerizing organisms among the human intestinal flora.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7288282

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  14 in total

1.  The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids.

Authors:  T Higuchi; N Hishida; T Isomura; H Takeshima; H Hayashi
Journal:  Gastroenterol Jpn       Date:  1992-04

Review 2.  Some pharmacokinetic considerations about homeostatic equilibrium of endogenous substances.

Authors:  A Marzo; A Rescigno; E Arrigoni Martelli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

Review 3.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

4.  Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.

Authors:  B Combes; R L Carithers; W C Maddrey; S Munoz; G Garcia-Tsao; G F Bonner; J L Boyer; V A Luketic; M L Shiffman; M G Peters; H White; R K Zetterman; R Risser; S S Rossi; A F Hofmann
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

5.  Characterization of NADP-dependent 7 beta-hydroxysteroid dehydrogenases from Peptostreptococcus productus and Eubacterium aerofaciens.

Authors:  S Hirano; N Masuda
Journal:  Appl Environ Microbiol       Date:  1982-05       Impact factor: 4.792

Review 6.  Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

7.  Tauroconjugation of cholic acid stimulates 7 alpha-dehydroxylation by fecal bacteria.

Authors:  J Van Eldere; P Celis; G De Pauw; E Lesaffre; H Eyssen
Journal:  Appl Environ Microbiol       Date:  1996-02       Impact factor: 4.792

8.  Contribution of the 7β-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic acid formation in the human colon.

Authors:  Ja-Young Lee; Hisashi Arai; Yusuke Nakamura; Satoru Fukiya; Masaru Wada; Atsushi Yokota
Journal:  J Lipid Res       Date:  2013-06-01       Impact factor: 5.922

9.  Formation of ursodeoxycholic acid from chenodeoxycholic acid by a 7 beta-hydroxysteroid dehydrogenase-elaborating Eubacterium aerofaciens strain cocultured with 7 alpha-hydroxysteroid dehydrogenase-elaborating organisms.

Authors:  I A MacDonald; Y P Rochon; D M Hutchison; L V Holdeman
Journal:  Appl Environ Microbiol       Date:  1982-11       Impact factor: 4.792

10.  Allspice and Clove As Source of Triterpene Acids Activating the G Protein-Coupled Bile Acid Receptor TGR5.

Authors:  Angela Ladurner; Martin Zehl; Ulrike Grienke; Christoph Hofstadler; Nadina Faur; Fátima C Pereira; David Berry; Verena M Dirsch; Judith M Rollinger
Journal:  Front Pharmacol       Date:  2017-07-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.